These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38149346)

  • 1. Late-onset mucopolysaccharidosis type IIIA mimicking Usher syndrome.
    De Falco A; Karali M; Criscuolo C; Testa F; Barillari MR; Scarpato M; Gaudieri V; Cuocolo A; Russo A; Nigro V; Simonelli F; Banfi S; Brunetti-Pierri N
    Am J Med Genet A; 2024 May; 194(5):e63517. PubMed ID: 38149346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Engineered
    Douek AM; Amiri Khabooshan M; Henry J; Stamatis SA; Kreuder F; Ramm G; Änkö ML; Wlodkowic D; Kaslin J
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA.
    Webber DL; Choo A; Hewson LJ; Trim PJ; Snel MF; Hopwood JJ; Richards RI; Hemsley KM; O'Keefe LV
    Exp Neurol; 2018 May; 303():38-47. PubMed ID: 29408731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications.
    Yogalingam G; Hopwood JJ
    Hum Mutat; 2001 Oct; 18(4):264-81. PubMed ID: 11668611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mutation p.Ser298Pro in the sulphamidase gene (SGSH) is associated with a slowly progressive clinical phenotype in mucopolysaccharidosis type IIIA (Sanfilippo A syndrome).
    Meyer A; Kossow K; Gal A; Steglich C; Mühlhausen C; Ullrich K; Braulke T; Muschol N
    Hum Mutat; 2008 May; 29(5):770. PubMed ID: 18407553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Postnatal and prenatal diagnosis of mucopolysaccharidosis type III (Sanfilippo syndrome)].
    Zhang WM; Shi HP; Meng Y; Li BT; Qiu ZQ; Liu JT
    Zhonghua Er Ke Za Zhi; 2008 Jun; 46(6):407-10. PubMed ID: 19099774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes.
    Fraldi A; Hemsley K; Crawley A; Lombardi A; Lau A; Sutherland L; Auricchio A; Ballabio A; Hopwood JJ
    Hum Mol Genet; 2007 Nov; 16(22):2693-702. PubMed ID: 17725987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual activity and proteasomal degradation of p.Ser298Pro sulfamidase identified in patients with a mild clinical phenotype of Sanfilippo A syndrome.
    Muschol N; Pohl S; Meyer A; Gal A; Ullrich K; Braulke T
    Am J Med Genet A; 2011 Jul; 155A(7):1634-9. PubMed ID: 21671382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioinformatics classification of mutations in patients with Mucopolysaccharidosis IIIA.
    Tanwar H; Kumar DT; Doss CGP; Zayed H
    Metab Brain Dis; 2019 Dec; 34(6):1577-1594. PubMed ID: 31385193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic scAAV9.U1a.hSGSH Delivery Corrects Brain Biochemistry in Mucopolysaccharidosis Type IIIA at Early and Later Stages of Disease.
    Saville JT; Derrick-Roberts ALK; McIntyre C; Fuller M
    Hum Gene Ther; 2021 Apr; 32(7-8):420-430. PubMed ID: 33339477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mutation of SGSH and clinical features analysis of mucopolysaccharidosis type IIIA.
    Li X; Xiao R; Chen B; Yang G; Zhang X; Fu Z; Fu J; Zhuang M; Huang Y
    Medicine (Baltimore); 2018 Dec; 97(52):e13758. PubMed ID: 30593151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
    Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of sulfamidase provides insight into the molecular pathology of mucopolysaccharidosis IIIA.
    Sidhu NS; Schreiber K; Pröpper K; Becker S; Usón I; Sheldrick GM; Gärtner J; Krätzner R; Steinfeld R
    Acta Crystallogr D Biol Crystallogr; 2014 May; 70(Pt 5):1321-35. PubMed ID: 24816101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Sanfilippo phenotype severity from immunoquantification of heparan-N-sulfamidase in cultured fibroblasts from mucopolysaccharidosis type IIIA patients.
    Perkins KJ; Muller V; Weber B; Hopwood JJ
    Mol Genet Metab; 2001 Aug; 73(4):306-12. PubMed ID: 11509012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a mutation causing mucopolysaccharidosis type IIIA in New Zealand Huntaway dogs.
    Yogalingam G; Pollard T; Gliddon B; Jolly RD; Hopwood JJ
    Genomics; 2002 Feb; 79(2):150-3. PubMed ID: 11829484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel conditional Sgsh knockout mouse model recapitulates phenotypic and neuropathic deficits of Sanfilippo syndrome.
    Lau AA; King BM; Thorsen CL; Hassiotis S; Beard H; Trim PJ; Whyte LS; Tamang SJ; Duplock SK; Snel MF; Hopwood JJ; Hemsley KM
    J Inherit Metab Dis; 2017 Sep; 40(5):715-724. PubMed ID: 28451919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High and prolonged sulfamidase secretion by the liver of MPS-IIIA mice following hydrodynamic tail vein delivery of antibiotic-free pFAR4 plasmid vector.
    Quiviger M; Arfi A; Mansard D; Delacotte L; Pastor M; Scherman D; Marie C
    Gene Ther; 2014 Dec; 21(12):1001-7. PubMed ID: 25142140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a Case of Pigmentary Retinopathy in Sanfilippo Syndrome Type IIIA Associated with Compound Heterozygous Mutations in the SGSH Gene.
    Wilkin J; Kerr NC; Byrd KW; Ward JC; Iannaccone A
    Ophthalmic Genet; 2016 Jun; 37(2):217-27. PubMed ID: 26331342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction.
    Magat J; Jones S; Baridon B; Agrawal V; Wong H; Giaramita A; Mangini L; Handyside B; Vitelli C; Parker M; Yeung N; Zhou Y; Pungor E; Slabodkin I; Gorostiza O; Aguilera A; Lo MJ; Alcozie S; Christianson TM; Tiger PMN; Vincelette J; Fong S; Gil G; Hague C; Lawrence R; Wendt DJ; Lebowitz JH; Bunting S; Bullens S; Crawford BE; Roy SM; Woloszynek JC
    J Biol Chem; 2022 Dec; 298(12):102625. PubMed ID: 36306823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design.
    Truxal KV; Fu H; McCarty DM; McNally KA; Kunkler KL; Zumberge NA; Martin L; Aylward SC; Alfano LN; Berry KM; Lowes LP; Corridore M; McKee C; McBride KL; Flanigan KM
    Mol Genet Metab; 2016 Nov; 119(3):239-248. PubMed ID: 27590925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.